TABLE 2.
Treatment modalities | Experimental models | Molecular mechanisms | References |
---|---|---|---|
Improving oxidative stress | Diabetic rats | ↑SOD, CAT, GPX, G6PDH | Garg and Bansal (2000) |
Ng et al. (2000) | |||
↓ MDA | Andallu et al. (2012) | ||
Liu et al. (2017) | |||
Islet β-cells | ↑ CCO, SDH, SOD | Liu et al. (2017) | |
Improving insulin resistance | Diabetic rats | ↑IRS-1/PI3K/Glut-4 | Cai et al. (2016) |
HepG2-cells | ↑IRS1/PI3K/Akt/GSK3β | Niu et al. (2020) | |
Diabetic rats | ↑IRS1/PI3K/Akt/GLUT4 | Liu et al. (2015) | |
Inhibits disaccharide absorption | Diabetic rats | ↓SGLT1, Na+/K + -ATP, GLUT2 | Li et al. (2013a) |
Li et al. (2013b) | |||
Diabetic mouse | ↓α-amylase, α-glucosidase | Silva et al. (2021a) | |
Regulation of lipid metabolism | Diabetic rats | ↑PPARα, Fas, HSL | Yamauchi et al. (2001) |
Ahmadian et al. (2010) | |||
↑pAMPK, ADPN, AdipoR1, AdipoR2 | Chang et al. (2013) | ||
↓ Hepatic glucose production | Fullerton et al. (2013) | ||
Fang and Judd (2018) | |||
HepG2-cells | ↓TC, TG, HDLc, Inflammatory factor secretion | Li et al. (2021a) | |
Diabetic rats | ↓ Fat absorption by the body | Ben Bacha et al. (2018) | |
↓ Fatty accumulation in the liver | Li et al. (2021b) | ||
Improving microbes in the gut | Diabetic mouse | ↓Lactobacillus, Dobrobacter, Streptococcus, Lactococcus, Vibrio thiobacillus | Hu et al. (2019) |
↑Bacteroidetes, Haemophilus, Ackermannia, Anaerobes |